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Abstract
Background: Retinoid X receptors (RXRs) are members of the nuclear receptor (NR) superfamily that mediate
signaling by 9-cis retinoic acid, a vitamin A (retinol) derivative. RXRs play key roles not only as homodimers but also
as heterodimeric partners—e.g., retinoic acid receptors (RARs), vitamin D receptors (VDRs), liver X receptors (LXRs),
and peroxisome proliferator-activated receptors (PPARs). The NR family was recently associated with allergic
diseases, but the role of RXRs in allergen-induced airway responses is not well defined.
The goal of this study is to elucidate the role of RXRs in asthma pathogenesis and the potency of RXR partial agonist in
the treatment of allergic airway inflammation and airway hyperresponsiveness using a murine model of asthma.
Methods: We investigated the effect of a novel RXR partial agonist (NEt-4IB) on the development of allergic airway
inflammation and airway hyperresponsiveness (AHR) in a murine model of asthma. Balb/c mice were sensitized
(days 0 and 14) and challenged (days 28–30) with ovalbumin (OVA), and airway inflammation and airway responses
were monitored 48 h after the last OVA challenge. NEt-4IB was administered orally on days 25 to 32.
Results: Oral administration of NEt-4IB significantly suppressed AHR and inflammatory cell accumulation in the airways
and attenuated the levels of TNF-α in the lung and IL-5, IL-13 and NO levels in bronchoalveolar lavage (BAL) fluid and
the number of periodic acid Schiff (PAS)-positive goblet cells in lung tissue. Treatment with NEt-4IB also significantly
suppressed NF-κB expression.
Conclusion: These data suggest that RXRs may be of crucial importance in the mechanism of allergic asthma and that
the novel RXR partial agonist NEt-4IB may be a promising candidate for the treatment of allergic airway inflammation
and airway hyperresponsiveness in a model of allergic asthma.
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Background
Asthma is characterized by chronic airway inflammation
and airway hyperresponsiveness (AHR). Airway inflam-
mation results from the influx of activated eosinophils
and T cells at the site of inflammation. T cells, particularly
T helper (Th) type 2 cells, which release IL-4, IL-5, and
IL-13, play a pivotal role in the development of AHR and
eosinophilic inflammation [1, 2]. However, asthma is a
heterogeneous disease with a complex pathophysiology.
Current management based on inhaled corticosteroids
and long-acting β2 agonists is effective in controlling
asthma in most patients, but some patients develop severe
asthma.
Retinoid X receptors (RXRs) are nuclear receptors that
control gene transcription dependent on ligand binding
[3] and act as homodimers or heterodimers with peroxi-
some proliferator-activated receptors (PPARs), liver X
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receptors (LXRs), and other nuclear receptors (NRs) [4–6].
Therefore, RXR agonists have multipotent effects on the
mechanism of airway inflammation and may play a critical
and powerful role in the treatment of heterogeneous
asthma. However, the relative proportions of RXRs interact-
ing as homodimers or heterodimers remain unclear
because RXRs are thought to function “permissively” as
immune modulators.
RXR agonists are effective in the treatment of several
diseases [7]. For example, the RXR full agonist Bexarotene
is used for the treatment of cutaneous T cell lymphoma [8]
and is also effective against type 2 diabetes, metabolic syn-
drome [9], Alzheimer’s disease [10], and Parkinson’s disease
in animal models [11]. Kakuta et al. reported that the novel
RXR full agonist NEt-TMN is potentially effective to reduce
adverse effects while retaining desired activities [12].
However, RXR full agonists, including NEt-TMN and
Bexarotene, are associated with strong adverse events, such
as weight gain, hepatomegaly, and blood triglyceride eleva-
tion, in the treatment of underlying diseases [12, 13].
To avoid these severe adverse events, we considered
that moderate activation of RXR might be sufficient to
regulate allergic inflammation, and we focused on the
production of new RXR partial agonists with lower max-
imum activation of RXR compared to RXR full agonists.
The novel RXR partial agonist NEt-4IB has a maximum
55% RXR efficacy compared with full agonists in a lu-
ciferase reporter gene assay, and 28 consecutive days’
administration of NEt-4IB resulted in no significant
adverse events [14]. Furthermore, we have investigated
the pharmacokinetics of NEt-4IB in vivo by positron
emission tomography (PET) and revealed an increase in
radioactivity in PET imaging of the lung [15].
Other NR superfamily members have been related to
allergic inflammation. A PPARγ agonist reduces the
response to cockroach allergen challenge in a murine
asthma model [16]. An LXR agonist reduces the
response to OVA-allergen challenge in a murine model of
asthma [17]. NR4A attenuates airway inflammation in a
mouse model of asthma [18]. These data suggest that
RXRs, which act as both homodimers and heterodimers
with other NRs, may be potential targets in the prevention
and management of heterogeneous asthma patients.
Therefore, we investigated for the first time the effect
of the RXR partial agonist NEt-4IB on the development
of AHR and eosinophilic airway inflammation in
OVA-sensitized and -challenged mice.
Methods
Animals
Female BALB/c mice at 8–12 weeks of age were pur-
chased from Charles River Japan, Inc. (Yokohama, Japan).
The mice were maintained on an OVA-free diet. All
experimental animals used in the present study were
housed under a protocol approved by the Institutional
Animal Care and Use Committee of Okayama University
Medical School (Okayama, Japan).
Sensitization and airway challenge
The mice were sensitized by intraperitoneal injection of
20 μg of OVA (Grade V; Sigma-Aldrich, St Louis, MO,
USA) emulsified in 2.25 mg of alum (Inject Alum; Pierce
Biotechnology, Rockford, IL, USA) on days 0 and 14.
The mice were subsequently challenged with OVA (1%
in saline) by ultrasonic nebulization for 20 min on
days 28, 29, and 30 (OVA/OVA). AHR was assessed
48 h after the last challenge, and tissues and cells were
obtained for further analysis [19]. Control mice were
non-sensitized but challenged with OVA (PBS/OVA).
Administration of the novel RXR partial agonist and
prednisone
The mice received the novel RXR partial agonist (NEt-4IB)
(0.0015, 0.005, and 0.015%) or prednisone (PSL) (0.005%)
daily on days 25 to 32 orally. The control mice received
vehicle.
Determination of airway responsiveness
A flexiVent small-animal ventilator (SCIREQ, Montreal,
PQ, Canada) was used to assess airway function (Snap-
shot) in anesthetized (intraperitoneal injection of sodium
pentobarbital, 70 mg/kg), mechanically ventilated ani-
mals. Changes in lung resistance (RL) were measured in
response to increasing doses of inhaled methacholine
(MCh) [20]. Airway responsiveness was assessed as the
change in airway function (150 breaths/min, tidal vol-
ume: 10 ml/kg) after challenge with aerosolized MCh
administered for 10 s (60 breaths/min, tidal volume:
20 ml/kg) at increasing concentrations (0, 1.56, 6.25,
12.5 and 25 mg/ml) [21]. Baseline RL values in response
to saline at 48 h were first determined. RL data were
continuously collected for up to 3 min, and the maximum
values were obtained.
BAL fluid
After the assessment of AHR, the lungs were lavaged
with Hanks’ balanced salt solution via the tracheal tube
(1 ml; 37 °C). The number of cells in the bronchoalveo-
lar lavage (BAL) fluid was determined. Cytospin slides
were stained and differentiated in a blinded manner by
counting at least 200 cells under light microscopy.
Histological studies of the lung
Lungs were fixed in 10% formalin. Blocks of lung tissue
were cut around the main bronchus and embedded in
paraffin blocks. Lung sections with a thickness of 4 μm
were stained with hematoxylin-eosin (H&E) to analyze
the difference between eosinophils and neutrophils, and
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periodic acid Schiff (PAS) was used to identify mucus-
containing cells (goblet cells) as previously described [22].
Measurement of cytokines, chemokines and nitric oxide
(NO)
The cytokine levels in the BAL fluid and homogenized
lung were measured by ELISA as previously described
[23]. All cytokine and chemokine ELISAs (R&D Systems,
Minneapolis, MN, USA) were performed according to
the manufacturer’s directions. The limits of detection
were 5 pg/ml for IL-4, 0.68 pg/ml for IL-5, 2 pg/ml for
IL-13, and 0.36 pg/ml for tumor necrosis factor alpha
(TNF-α). For the preparation of lung homogenates, lung
tissue was frozen at −70 °C immediately after euthanasia.
Next, the lung tissue was mixed with a PBS-0.1%
Triton-X100 solution containing proteinase inhibitors at
a 1:2.5 ratio of weight per volume (Sigma-Aldrich). The
specimens were homogenized and then centrifuged at
14,000 rpm for 30 min. The supernatants were frozen
at −70 °C until analysis. NO with BAL fluid was mea-
sured using a nitrate/nitrite fluorometric assay kit
(Cayman chemical, Ann Arbor, MI, USA) as previously
described [24].
Cell preparation and culture
Lung mononuclear cells (MNCs) from OVA-sensitized
and -challenged mice were isolated as previously de-
scribed following collagenase digestion [22]. Lung MNCs
were cultured for 24 h in 96-well round-bottom plates
in the presence or absence of OVA (10 μg/ml). Ten days
after OVA-sensitization, the spleens were removed from
mice and placed in PBS. The tissue was dispersed into
single-cell suspensions, and spleen MNCs were purified
by Ficoll-Hypaque gradient centrifugation (Sigma-Aldrich).
The cells (4 × 105) were then cultured for 48 h in 96-well
round-bottom plates in the presence or absence of OVA
(10 μg/ml) and drugs (NEt-4IB or PSL) as previously de-
scribed [25]. The cytokine levels in the culture supernatants
were measured by ELISA.
Measurements of blood parameters
Triglyceride (TG) levels were measured using a Fuji Dry
Chem system (Dry Chem 4000 V; Fuji Medical Co.,
Tokyo, Japan).
Flow cytometry
After lung cell purification, intracytoplasmic cytokine
staining was performed as previously described [26, 27].
The cells were stained for cell surface markers with PE-
conjugated anti-CD4 (BD Biosciences, Franklin Lakes,
NJ, USA), FITC-conjugated anti-CD8 (BD Biosciences),
or APC-conjugated anti-CD3 (BD Biosciences) and then
analyzed using a MACS Quant flow cytometer (Miltenyi
Biotec, Auburn, CA, USA) with FlowJo software (TreeStar,
Ashland, OR, USA). The numbers of cytokine-producing
CD4+ or CD8+ T cells per lung were calculated from the
percentages of cytokine-producing cells and the numbers
of CD4+ or CD8+ T cells isolated from the lung. The
cells were also stained for cell surface markers with
APC-conjugated anti-CD11b (BD Biosciences) and FITC-
conjugated anti-CD11c (BD Biosciences).
Total RNA isolation and quantitative real-time PCR
The left lung was homogenized, and total RNA was
extracted using TRIzol reagent (Invitrogen, Carlsbad,
CA, USA), followed by treatment with DNase (Qiagen,
Valencia, CA, USA) according to the manufacturer’s
instructions. Reverse transcription was performed using
oligo (dT) primers and Invitrogen Superscript II Reverse
Transcriptase (Life Technologies, Grand Island, NY, USA)
to obtain cDNA for PCR. Quantitative real-time PCR was
performed in a 25-μl reaction using FastStart Essential
DNA Green Master (Roche, Basel, Switzerland). The
primers sequences were as follows: NF-κB, forward, 5-
CAACAGATGGGCTACACAGAGG-3, and reverse, 5-
GGAAGACGAGAGAGGCAGACA-3; GAPDH, forward,
5-TATGTCGTGGAGTCTACTGGT-3, and reverse, 5-
GAGTTGTCATATTTCTCGTGG-3. The relative expres-
sion levels of each target were normalized to GAPDH and
calculated using the ΔΔ cycle threshold method. There
were no differences in GAPDH expression among the
groups [28].
Immunoblotting
Protein extracts were prepared from homogenates sus-
pended in PBS-0.1% Triton-X100 solution containing
proteinase inhibitors (BD Biosciences) and centrifuged at
14,000 rpm min at 4 °C. After quantification using the
Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA), SDS
was added to the supernatant. Aliquots of the supernatant,
each containing 30 μg of protein, were separated by
SDS-PAGE and electrically transferred to nitrocellulose
membranes. Nonspecific binding sites were blocked
with Tris-buffered saline (TBS) containing 5% nonfat dry
powdered milk (wt/vol) for 1 h at room temperature. After
a brief rinse with TBS containing 0.1% Tween 20 (TBST),
the protein blots were incubated with 1:50,000 diluted anti-
NF-κB antibody (cat. no. ab32536, Abcam, Cambridge,
MA, USA), 1:1000 diluted anti-inducible nitric oxide
synthase antibody (cat. no. ab178945, Abcam) and 1:5000
diluted anti-β-actin (cat. no. ab8227, Abcam) overnight at
4 °C. The secondary antibody was anti-rabbit IgG
(horseradish peroxidase-linked, species-specific whole
antibodies; GE Healthcare, Buckinghamshire, UK), which
was used at a 1:5000 dilution.
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Statistical analysis
All results are expressed as the mean ± standard error of
the mean (SEM). ANOVA was used to determine the
levels of difference among all groups. Pairs of groups of
samples distributed parametrically were compared by
unpaired two-tailed Student’s t-test, and those samples
distributed nonparametrically were compared by the
Mann–Whitney U test. Significance was assumed at P
values <0.05.
Results
Treatment with a novel RXR partial agonist attenuates
AHR and airway inflammation in OVA-sensitized and
-challenged mice
We assessed the AHR of OVA-sensitized and -challenged
mice treated with vehicle (OVA/OVA/vehicle) to increasing
doses of inhaled MCh. OVA/OVA/vehicle mice developed
AHR compared with the non-sensitized but OVA-
challenged mice treated with vehicle (PBS/OVA/vehicle).
The administration of the novel RXR partial agonist
(NEt-4IB) significantly attenuated the increase in AHR
throughout the MCh dose–response curve in a dose-
dependent manner (Table 1, Fig. 1A) and prevented the
increase in the number of lymphocytes and eosinophils
in the BAL fluid compared with OVA/OVA/vehicle mice
(Fig. 1B).
Effects of prednisone on airway inflammation and
hyperresponsiveness in OVA-sensitized and -challenged
mice
PSL-treated mice exhibited a reduced number of macro-
phages and eosinophils in the BAL fluid compared to
OVA/OVA/vehicle mice and OVA/OVA/NEt-4IB mice
(Fig. 1B). The administration of PSL significantly attenu-
ated the increase in AHR; however, interestingly, no sig-
nificant difference was observed between OVA/OVA/PSL
mice and OVA/OVA/NEt-4IB mice (Table 1).
Localization of inflammatory cells and mucus production
in lung tissue
The development of AHR is associated with inflammatory
changes in lung tissue [23]. To determine if treatment
with NEt-4IB affected inflammatory changes in the lung,
we assessed tissue inflammation. Hematoxylin-eosin-
stained lung tissue revealed significant increases in inflam-
matory cells in peribronchial inflammation in OVA/OVA/
vehicle mice compared with PBS/OVA/vehicle mice. Mice
treated with NEt-4IB exhibited reduced numbers of
eosinophils and lymphocytes in lung tissue (Fig. 1C). Lung
sections were stained with PAS to identify mucus-containing
cells in the airway epithelium. A significant increase in
PAS-positive goblet cell hyperplasia was observed in
OVA/OVA/vehicle mice. Treatment with NEt-4IB
significantly reduced the number of PAS-positive cells
per millimeter of basement membrane (Fig. 1D).
Treatment with NEt-4IB suppresses IL-5, IL-13 and NO
levels in BAL fluid and TNF-α and iNOS in the lung
Cytokine levels in BAL fluid and the lung were measured
by ELISA. Treatment with vehicle resulted in significant
increases in the levels of Th2 cytokines in BAL fluid
and TNF-α in the lung. By contrast, treatment with
NEt-4IB significantly reduced not only IL-5 and IL-13
levels but also TNF-α levels compared with vehicle-
treated OVA/OVA mice (Fig. 1E a-d). IFN-γ was not
detected even in OVA/OVA/vehicle mice in this study
(data not shown).
In asthmatic patients, the level of nitric oxide, which is
produced endogenously in the lung by nitric oxide syn-
thase to elicit multiple physiological functions, can be
measured in exhaled breath [29]. However, a deficiency
in inducible nitric oxide synthase (iNOS) suppresses
ozone-induced airway tissue injury and LPS-induced acute
airway inflammation in mice [30, 31]. NO inhibitors block
eosinophil recruitment in the lungs [32]. NO is also a
potent vasodilator in the bronchial circulation and may
play a major role in airway circulation [33]. In the present
study, the level of NO in the BAL fluid was significantly
suppressed in OVA/OVA NEt-4IB-treated mice compared
with OVA/OVA vehicle-treated mice (Fig. 1E e), although
a significant difference was not recognized among three
groups in the expression levels of iNOS in the lung
(Fig. 1E f ).
Table 1 Dose-dependent effects of NEt-4IB and PSL on AHR
Methacholine (mg/mL) 0 1 6 12 25
PBS/OVA/Vehicle 0.93 ± 0.19 1.57 ± 0.15 2.22 ± 0.20 2.93 ± 0.3.3 3.95 ± 0.53
OVA/OVA/Vehicle 1.19 ± 0.26 2.63 ± 0.51 5.31 ± 0.52* 7.25 ± 0.45* 11.27 ± 0.87*
OVA/OVA/NEt-4IB 0.0015% 0.82 ± 0.05 2.14 ± 0.31 4.26 ± 0.59 5.81 ± 0.73 9.93 ± 1.66
OVA/OVA/NEt-4IB 0.005% 0.84 ± 0.10 1.66 ± 0.20 3.97 ± 0.44 6.07 ± 0.41 8.75 ± 0.56
OVA/OVA/NEt-4IB 0.015% 1.00 ± 0.15 2.10 ± 0.25 3.57 ± 0.52 5.28 ± 0.37** 7.14 ± 0.31**
OVA/OVA/PSL 0.005% 0.89 ± 0.06 1.52 ± 0.10 3.13 ± 0.34** 4.73 ± 0.47** 6.38 ± 0.42**
The results for each group are expressed as the mean RL ± SEM (cmH2O s/ml) (n = 8–12 in each group). *Significant difference (P < 0.05) between PBS/OVA/Vehicle
and OVA/OVA/Vehicle. **Significant difference (P < 0.05) between OVA/OVA/Vehicle and OVA/OVA/NEt-4IB or OVA/OVA/PSL
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Fig. 1 Treatment with NEt-4IB and PSL attenuates AHR and airway inflammation. a AHR. b Cell composition in BAL fluid. c H&E-stained lung tissue
(final magnification: ×400). (a) PBS/OVA/Vehicle, (b) OVA/OVA/Vehicle, (c) OVA/OVA/NEt-4IB, (d) inflammatory cell numbers in the peribronchial
and perivascular tissue. d Treatment with NEt-4IB suppresses goblet cell metaplasia (final magnification: ×1000). (a) PBS/OVA/Vehicle, (b) OVA/
OVA/Vehicle, (c) OVA/OVA/NEt-4IB, (d) the number of mucus-positive cells. e (a) IL-4, (b) IL-5, (c) IL-13 in BAL fluid, (d) TNF-α in the lung, (e) NO in
BAL fluid. n = 8–20 in each group. (f) The expression levels of iNOS in the lung were determined by Western blotting as described in the Methods.
n = 4 in each group. f Serum levels of (a) total IgE, (b) anti-OVA IgG1, (c) anti-OVA IgE. n = 8–20 in each group. The results for each group are
expressed as the mean ± SEM. Mac macrophage, Eos eosinophil, Lym lymphocyte, and Neu neutrophil. * Significant differences (P < 0.05) between
PBS/OVA/Vehicle and OVA/OVA/Vehicle. # Significant differences (P < 0.05) between OVA/OVA/Vehicle and OVA/OVA/NEt-4IB. † Significant difference
(P < 0.05) between OVA/OVA/NEt-4IB and OVA/OVA/PSL
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Treatment with the RXR partial agonist suppresses serum
anti-OVA IgE antibody levels
The serum Ig levels in OVA/OVA/vehicle mice were
elevated compared with those in PBS/OVA/vehicle mice,
and treatment with NEt-4IB significantly suppressed
OVA-specific IgE compared with OVA/OVA/vehicle mice
(Fig. 1F).
The numbers of CD4+ T cells, CD8+ T cells, CD11b+ cells,
and CD11c+ cells in the lung
To determine if the accumulation of T cells in the
airways of sensitized and challenged mice was affected
by treatment with NEt-4IB, lung cells were isolated, and
the numbers of both CD4+ and CD8+ T cells were
determined by flow cytometry. The numbers of CD4+
and CD8+ T cells were significantly lower in the lungs of
NEt-4IB-treated mice compared to vehicle-treated mice
(Fig. 2a, b). These data indicate that treatment with NEt-
4IB attenuated the accumulation of CD4+ and CD8+ T
cells in the airways of OVA-sensitized mice after chal-
lenge. The numbers of CD11b+ cells but not CD11c+ cells
were significantly lower in the lungs of NEt-4IB-treated
mice compared to vehicle-treated mice (Fig. 2c, d).
Cytokine production by lung and spleen MNCs in vitro
We assessed cytokine production from lung MNCs
(Fig. 3A, B) and spleen MNCs (Fig. 3C, D) in vitro. Lung
MNCs were isolated from OVA-sensitized and -challenged
and vehicle mice (OVA/OVA/vehicle). Re-stimulation with
OVA (10 μg/ml) for 24 h significantly increased Th2
cytokine levels in the lung MNC culture supernatants.
However, in NEt-4IB-treated mice (OVA/OVA/NEt-4IB),
both IL-5 and IL-13 levels were significantly suppressed
in OVA-re-stimulated culture supernatants (Fig. 3B
a-c). Next, spleen MNCs isolated 10 days after OVA
sensitization in mice were stimulated with OVA (10 μg/
ml) for 48 h in the presence or absence of NEt-4IB or
PSL in vitro. The levels of Th2 cytokines were significantly
increased in the culture supernatants from spleen MNCs
after culture with OVA. Treatment with NEt-4IB (10 μM)
significantly decreased the levels of IL-5 and IL-13 in the
culture supernatants compared with the non-treated
group in vitro. PSL (1 μM) had a significant effect on
cytokine levels (Fig. 3D a-c).
Triglyceride value in the blood
To assess adverse events associated with NEt-4IB, we
measured serum TG levels, which were 331.3 ± 13.9,
332.1 ± 30.9, and 367.7 ± 48.5 ml/dL in PBS/OVA/
vehicle, OVA/OVA/vehicle and OVA/OVA/NEt-4IB mice,
respectively. There were no significant differences
between OVA/OVA/vehicle mice and OVA/OVA/
NEt-4IB mice. Additionally, there were no significant
differences in liver size between the two groups (data
not shown).
Fig. 2 Numbers of CD4+, CD8+ T cells and CD11b+, CD11c+cells in the lung. The numbers of a CD4+, b CD8+ T cells, c CD11b+ cells, and
d CD11c+ cells in the lung were calculated as described in the Methods section. n = 8–12 in each group. The results for each group are
expressed as the mean ± SEM. * Significant differences (P < 0.05) between PBS/OVA/Vehicle and OVA/OVA/Vehicle. # Significant differences
(P < 0.05) between OVA/OVA/Vehicle and OVA/OVA/NEt-4IB
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Treatment with NEt-4IB suppresses NF-κB expression in
the lung tissues
NF-κB is a transcription factor that acts as a key regula-
tor of immune and inflammatory genes, and activation
of the NF-κB pathway has been implicated in asthma in
both experimental models and humans [34, 35]. The
NF-κB mRNA and protein levels were significantly
increased in OVA/OVA vehicle-treated mice compared
to PBS/OVA mice. Treatment with this partial agonist
significantly attenuated the levels of NF-κB compared
with OVA/OVA vehicle-treated mice (Fig. 4).
Discussion
RXRs function not only as homodimers but also as
permissive heterodimers with other NR superfamily
members, including VDR, PPAR, and LXR. Therefore,
an RXR agonist may exert potential effects on both
RXRs and PPAR/RXR or LXR/RXR. A PPARγ agonist
ameliorates experimental autoimmune encephalomyelitis
or human central nerve system demyelinating diseases in
animal models [36]. Additionally, agonists of PPARγ, LXR,
and NR4A have some effects on allergic inflammation
[16–18]. However, the role of RXR in mouse models of
asthma remains unclear.
RXR full agonists are reported to be effective in the
treatment of several diseases. In particular, in humans,
Bexarotene is used for the treatment of cutaneous T-cell
lymphoma [8, 37]. However, RXR full agonists are associ-
ated with strong adverse events, including the elevation of
blood triglycerides, hepatomegaly and hypothyroidism
[12, 13]. Accordingly, we developed a novel RXR partial
agonist that displays no significant adverse events even
with 28 consecutive days’ administration compared with
full agonists [14]. In this study, elevations of TG levels and
liver size were not recognized in OVA/OVA/NEt-4IB mice
compared with OVA/OVA/vehicle mice. These data sug-
gest that treatment with NEt-4IB in allergic inflammation
is effective without severe adverse events.
Fig. 3 IL-4, IL-5, and IL-13 levels in culture supernatants from lung and spleen MNCs. a Experimental protocol. Lung mononuclear cells (MNCs)
were isolated from OVA-sensitized and -challenged mice and were cultured for 24 h in the presence or absence of OVA (10 μg/ml) as previously
described in the Methods [22]. b (a) IL-4, (b) IL-5, and (c) IL-13 levels in supernatants from cultured lung MNCs isolated from OVA-sensitized
and -challenged mice in the presence or absence of OVA (10 μg/ml) were determined by ELISA. c Experimental protocol. Spleen MNCs were
isolated from OVA-sensitized mice and were stimulated with OVA for 48 h in the presence or absence of NEt-4IB (1, 10 μM) or prednisone
(1 μM) as previously described in the Methods [25]. d (a) IL-4, (b) IL-5, and (c) IL-13 levels in supernatants from cultured spleen MNCs isolated
from OVA-sensitized mice in the presence or absence of OVA (10 μg/ml) and NEt-4IB (1, 10 μM) or PSL (1 μM) were determined by ELISA.
n = 8–12 in each group. The results for each group are expressed as the mean ± SEM. * Significant differences (P < 0.05) between medium-stimulated
OVA/OVA/Vehicle and OVA-stimulated OVA/OVA/Vehicle. # Significant differences between OVA-stimulated OVA/OVA/Vehicle and OVA/OVA/NEt-4IB
or OVA/OVA/PSL
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In the present study, we demonstrated for the first
time the potential of our novel RXR selective partial
agonist NEt-4IB to present AHR and airway inflamma-
tion. Our results clearly show that AHR was significantly
suppressed in NEt-4IB-treated mice in a dose-dependent
manner, with attenuation of not only eosinophilic airway
inflammation and Th2 cytokine production in the BAL
fluid and goblet cell metaplasia in the lung but also
TNF-α levels in the lung. These data also suggest that
RXR plays critical roles in allergen-induced allergic
inflammation.
We previously demonstrated that both CD4+ T cells
and CD8+ T cells play pivotal roles in the development
of AHR and airway inflammation [26]. In our study,
treatment with NEt-4IB significantly decreased the num-
ber of CD8+ T cells as well as CD4+ T cells compared
with vehicle-treated mice. Furthermore, the numbers of
CD11b+ cells which are recognized as monocytes/
macrophages and to a lower extent on granulocytes, NK
cells, and a subset of dendritic cells in the lung were
significantly lower in NEt-4IB treated mice.
To assess the mechanism of NEt-4IB, we performed in
vitro experiments. The levels of IL-5 and IL-13 in the
culture supernatant in OVA-re-stimulated lung MNCs
isolated from OVA-sensitized and -challenged mice were
significantly suppressed in OVA/OVA/NEt-4IB mice
compared with OVA/OVA/vehicle mice. IL-5 and IL-13
levels in the OVA-re-stimulated spleen MNCs isolated
from OVA-sensitized mice were significantly increased,
and treatment with NEt-4IB in vitro also significantly
attenuated the production of IL-5 and IL-13 in the cul-
ture supernatants in a dose-dependent manner. Moreover,
there was no significant difference in Th2 cytokine produc-
tion between the NEt-4IB (10 μM)-treatment group and
PSL (1 μM)-treatment group. These results suggest that
treatment with NEt-4IB suppresses Th2 cytokines both in
the sensitization phase and effector phase and may be ef-
fective in regulating Th2-related allergic inflammation.
TNF-α is a pro-inflammatory Th1 cytokine that induces
airway inflammation and hyperresponsiveness, mucus hy-
persecretion, and the activation of macrophages. In two
small, placebo-controlled, double-blind, crossover studies
of patients with corticosteroid refractory asthma, treat-
ment with anti-TNF-α antibody (etanercept) resulted in
clinical improvement in PC20, quality-of-life scores, and
lung function [38] and improvement in asthma control
questionnaire scores with reductions in the use of nebu-
lized β2 agonists [39]. However, in a subsequent larger
study in uncontrolled severe asthma, the anti-TNF-α
antibody had no overall beneficial effects and increased
the risk of serious side effects, although a post-hoc analysis
suggested that patients with substantial bronchodilator
reversibility had fewer exacerbations [40, 41]. These data
may indicate the importance of TNF-α in the innate
immune responses and suggest that complete suppression
of TNF-α may be a critical and problematic approach.
However, NEt-4IB is a partial RXR agonist, and treatment
with NEt-4IB significantly suppressed TNF-α levels in the
lung compared with vehicle-treated OVA/OVA mice in
this study.
TNF-α triggers the activation of the inhibitor kappa-B
(IκB) kinase (IKK)/NF-κB and mitogen-activated protein
kinase (MAPK)/AP-1 pathways [42], and NF-κB trans-
location from the cytoplasm to the nucleus and binding
Fig. 4 Treatment with NEt-4IB suppresses NF-κB expression in the lung. The expression levels of NF-κB were determined by RT-PCR (a) and Western
blotting (b) as described in the Methods. n = 4 in each group * Significant differences (P < 0.05) between PBS/OVA/Vehicle and OVA/OVA/Vehicle.
# Significant differences (P < 0.05) between OVA/OVA/Vehicle and OVA/OVA/NEt-4IB
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to the promoter modulate the expression of inflamma-
tory genes, including iNOS, inflammatory cytokines and
chemokines. Additionally, several studies have reported
that the activation of the NF-κB pathway is involved in
both experimental murine asthma models and human
asthmatics [34, 35]. Furthermore, iNOS produces nitric
oxide (NO), which acts as a toxic radical and can cause
tissue and cell damage. The over-production of NO may
recruit eosinophils into the airway, resulting in the
aggravation of airway inflammation [43]. Na et al.
reported that RXR may directly modulate NF-κB-DNA
interactions by forming a complex with NF-κB that
cannot bind to κB sites [44]. In the present study, treat-
ment with NEt-4IB significantly reduced NO levels in
BAL fluid as well as TNF-α in lung homogenates
compared with OVA/OVA vehicle-treated mice. These
data suggest that NEt-4IB may affect eosinophilic in-
flammation by decreasing NO via the TNF-α/NF-κB
pathway or directly interacting with NF-κB.
Conclusion
These findings indicate the therapeutic potential of the
novel RXR partial agonist NEt-4IB in the development
of allergic airway inflammation and AHR. Although
additional studies will be required to demonstrate that
NEt-4IB may partially and permissively effect heterodi-
meric partners such as PPARs, NEt-4IB may be a promis-
ing candidate for the treatment of allergic airway
inflammation and airway hyperresponsiveness in Th2 high
allergic asthma.
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